| Code | CSB-RA867113MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to fezakinumab, designed to specifically bind and neutralize interleukin-22 (IL-22), a member of the IL-10 cytokine family. IL-22 is primarily produced by immune cells including Th17 and Th22 cells, and plays a crucial role in epithelial barrier integrity, tissue repair, and antimicrobial defense. This cytokine signals through the IL-22 receptor complex, promoting keratinocyte proliferation and production of antimicrobial peptides. Dysregulated IL-22 activity has been implicated in various inflammatory and autoimmune conditions, particularly psoriasis, atopic dermatitis, rheumatoid arthritis, and inflammatory bowel disease, where excessive IL-22 contributes to pathological inflammation and tissue remodeling.
Fezakinumab, the reference antibody, is a humanized IgG1 monoclonal antibody that was evaluated in clinical trials for moderate-to-severe plaque psoriasis and atopic dermatitis. This biosimilar provides researchers with a valuable tool for investigating IL-22-mediated signaling pathways, studying the cytokine's role in immune-mediated diseases, and exploring therapeutic mechanisms in preclinical models of inflammatory disorders.
There are currently no reviews for this product.